RecallRadar
LowReported November 5, 2025

Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blist…

Recalled by Endo USA, Inc.

Product image for Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-119-91
Product image via DailyMed (National Library of Medicine). It may show general packaging and not the exact recalled lot — always confirm using the codes below.

Class III — least serious

Using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).

Endo USA, Inc. has recalled Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blist…, according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on November 5, 2025 and was initiated on October 10, 2025. It is classified as a Class III recall, which means using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).

Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.

What was recalled?

This recall covers Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blist…, with approximately 2,035 cartons affected. The company behind the recall is Endo USA, Inc., based in Malvern, PA. The FDA describes the product as: “Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-119-91”

Why was Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blist… recalled?

According to the FDA, the stated reason for the recall is: “Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.” In plain terms, this recall relates to a chemical impurity.

This recall involves an unwanted chemical detected in the medicine — often a nitrosamine impurity, which regulators limit because long-term exposure above set levels may increase health risks. Regulators recall affected batches as a precaution. Health authorities generally advise talking to a doctor or pharmacist before stopping a prescribed medicine.

What should you do?

If you think you may have bought Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blist…, compare it against the product description and identifying codes (Lot #: 550172201, Exp. Date JAN-26; 550184801, Exp. Date MAR-26; 550204001, Exp. Date JUL-26) before using it. This recall is currently listed as ongoing.

The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact Endo USA, Inc. or your local health authority.

About this recall

This recall was distributed in PA. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.

Full recall details

Status
Ongoing
Date reported
November 5, 2025
Recall started
October 10, 2025
Distributed in
PA
What was recalled
Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-119-91
Why it was recalled (as stated by the FDA)
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
How to identify the affected product
Lot #: 550172201, Exp. Date JAN-26; 550184801, Exp. Date MAR-26; 550204001, Exp. Date JUL-26
Amount recalled
2,035 cartons

What you can do

Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.

Quick answers

Why was Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blist… recalled?+

According to the FDA: Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.

How serious is this recall?+

Class III — least serious. Using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).

What should I do if I have Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blist…?+

Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.

Share this recall:PostShareEmail
View the official FDA record

Opens the U.S. Food and Drug Administration (FDA) data for this recall.

Recall number: D-0142-2026. Information last synced from the FDA on July 5, 2026.

Related recalls